BioSpace News Archive

Envista Holdings Corporation (NYSE: NVST) (“Envista”) today announced that the company will participate in the J.P. Morgan Healthcare Conference on Monday, January 8, 2024 at 3:00 – 3:40 PM PST.

Palatin Technologies, Inc. announced it received a notice from the staff of NYSE American LLC approving Palatin’s plan to come into compliance with the Exchange’s continued listing standards under Section 1003 and of the NYSE American Company Guide.

Henry Schein, Inc., the world’s largest provider of health care solutions to office-based dental and medical practitioners, announced that its Board of Directors has appointed Carole T. Faig as an independent director to serve until the 2024 Annual Meeting of Stockholders in May, when she is expected to stand for re-election to the Board by a vote of the Company’s stockholders.

Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today announced that Mitchell Gold, M.D., Executive Chairman and Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday.

TC BioPharm PLC a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer, announced that the creation of a new Commercial Development Division, which will be headed by Dr. Lauren Bor, PhD.

Schweiger Dermatology Group has announced it has acquired the two New Jersey practices previously owned by NavaDerm Partners: Scherl Dermatology in Englewood Cliffs, founded by Dr. Sharon Scherl, and Millburn Laser Center in Millburn, New Jersey, founded by Dr. Eric Siegel. Both Drs. Siegel and Scherl will continue seeing patients at their respective offices.

Pixium Vision SA announces that following ‘s hearing, the Paris Commercial Court will issue its decision on January 16, 2024 on the takeover offer filed on November 20, 2023 and the opening of judicial liquidation proceedings.

Agno Pharma, a US-based, global pharmaceutical contract development and manufacturing organization, announced that it will acquire the Lubrizol Particle Sciences Inc. business.

FamGenix and Spesana, two leading health-tech companies, are thrilled to announce a strategic partnership that promises to propel the advancement of precision medicine and transform the solutions available to clinicians & patients.